BioSpace News Archive

New guidance from the American Academy of Neurology concludes that closure of a common heart defect called a patent foramen ovale may be recommended for some people who have had a stroke.

The U.S. Food and Drug Administration announced the following actions taken in its ongoing response effort to the COVID-19 pandemic

In a first-time disclosure of IPN60090, a small-molecule inhibitor of the metabolic enzyme glutaminase (GLS1), researchers from The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery division and Ipsen Biopharmaceuticals reported the preclinical discovery and early-stage clinical development of this novel drug.

Synergy CHC Corp. (OTCQB: SNYR) (“Synergy” or the “Company”), a consumer health care & beauty company, today reported results for the fiscal year ended December 31, 2019.

REFINE USA, LLC, a leader in cosmetic medical aesthetic devices since 2006, has been granted a class II medical clearance from the FDA for its medical grade Microneedling device, Rejuvapen NXT

The Simón Bolívar Foundation Inc., the non-profit, private foundation of CITGO Petroleum Corporation, is awarding up to $200,000 to five non-profit organizations working in health-focused initiatives for vulnerable Venezuelans as part of its COVID-19 Small Grants Program.

Abiomed (NASDAQ: ABMD), maker of the Impella heart pump, has acquired Breethe, developer of a novel extracorporeal membrane oxygenation (ECMO) system that will complement and expand Abiomed’s product portfolio to more comprehensively serve the needs of patients whose lungs can no longer provide sufficient oxygenation,

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”) is pleased to announce new data are scheduled to be presented in two poster presentations during the American Society of Clinical Oncology’s (ASCO) Annual Meeting, a leading global scientific meeting for oncology professionals, taking place from 29 May – 31 May 2020

A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

ARTES Biotechnology, the German-based biotech company specializing in process development for recombinant vaccines, entered development of SARS-CoV-2 vaccine candidates based on its virus-like particle (VLP) based platform technologies METAVAX® and SplitCore.